clinical trial · NCT05741294
A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses
Almirall, S.A.·phase4·completed·n = 334
Actinic KeratosisTirbanibulin 2.5 mg ointment
brief summary
The purpose of the study is to assess treatment satisfaction on Day 57 in participants with Actinic Keratoses (AK) of the face or scalp following treatment with tirbanibulin ointment 1 percent (%) administered once daily for 5 consecutive days.
started
Jan 20, 2023
primary completion
Jan 19, 2024
completion
Jan 19, 2024
last updated
Feb 20, 2025
official title
Open Phase IV Study to Assess the Impact of Tirbanibulin on the Wellbeing of Patients With Actinic Keratoses (TIRBASKIN)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol